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Questions for Panel II
DR. MAHONEY: Autonomy and privacy are major concerns with respect to gathering
and dealing with genetic identification of ourselves and others. What about a group
of individuals who sacrifice their privacy interests automatically-that is, our infants
and children? We talked earlier today about the rights of adults to say no, that they
don't have to receive genetic information and they don't have to undergo various
medical interventions. But we now are talking about storing DNA from birth. We
heard examples of it, and parents may be pressured over and over again for the
benefit of their children to examine this DNA. Who will speak for these children?
Will we have a generation from now onwhich possesses no privacy?
DR. REILLY: In our society, parents do speak for the children. I don't see that fact
changing because ofgenetic testing; I see it as yet another permutation ofa problem
that occurs all thetime. Itmaybe that parents need tobeeducated aboutsayingno to
certain requests in a way they've never considered before. I recall reading about two
primary care physicians, who essentially said that for years in their practice they had
been routinely signing and mailing in physical examination forms and revealing data
about individuals to employers, school systems, and thelike, and theywerebeginning
to wonder if, instead, they should counsel patients about the consequences of
revealingthis kind ofinformation. I can't thinkofanybetter advocate for achild than
the well-informed parent.
DR. BILLINGS: With respect to the insurance industry, I would think that we would
handle pediatric data, genetic data, much as we would with the adults. A lot of
attention must be directed to confidentiality.
DR. POKORSKI: I think that parents and family are the bestjudge of how this genetic
information and which information should be taken. What I consider so striking
about it is that there is very little informed consent in terms ofwhat information is
garnered about the newborn. Currently, the parents are very much unaware ofwhat
information isgenerated about theirchildren, but theyoften suffer the consequences
of that information. For instance, in our survey we had several responses from
individuals whose children had biochemical disorders, identified through neonatal
screening, and who had a variety of problems with their employers. The diets were
too expensive, and they had lost state entitlements because of state cutbacks. These,
of course, aren't specific to genetic disorders, but they are burdens which people
have to bear.
DR. MAHONEY: I think that for a long time some parents have been aware of the
discrimination which occurs when they identify their child to the school system as
having some disorder. It may become ourjob to educate parents in the genetic field
aswell.
QUESTION: Howdo the insurance companies make decisions aboutgeneticdisorders?
DR. REILLY: The insurance industry is a regulated industry, and one can cite loads of
examples where public policy makers have overridden insurance companies and
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required coverage. The classic example is infertility therapies, in vitro fertilization
and the like, where, state by state, legislation is being passed to require that this area
be paid for as a health benefit for individuals. The insurance industry has accepted
this added cost, but there are limits to that acceptance. Several years ago, HIV
testing was required by certain insurance companies before they would provide life
insurance. The state of West Virginia tried to require them to do without HIV
testing. The companies then refused to write life insurance, and the state pulled
back. Ifthere is private insurance in this country, the companies can't operate above
a certain level of cost. One could, however, set rules specifically aimed at testing in
children, and the insurance companies could probably tolerate it.
DR. POKORSKI: With group insurance or health insurance in general, the big payers
are employers. They are responsible for more than Blue Cross, Blue Shield, or the
private insurance companies. The self-insured companies play the biggest role. The
insurance company agrees to administer a plan and keep charges within a rough
arena. Employers can add virtually anything, but it's at the risk of losing something
else, because they have a fixed amount of money. Are they going to cut retiree
benefits, are they going to increase deductibles-there are only a certain number of
choices. It's not just an insurance issue; in fact, it's more of an employer issue. The
question is,what should insurance companies inthe United Statesprovide as abase?
DR. REILLY: Let's imagine that ayearfrom nowwe've identified a set ofmutations for
cystic fibrosis (CF) that allows us to identify 95 percent of CF carriers, and HMOs
decide to do CF testing as a health benefit. People get tested; three years later
they're in other jobs; a couple is working, they're married, and they disclose that
they've known for several years they are carriers for CF. That might keep them from
enteringthe group health insurance poolwith that other employer.
DR. POKORSKI: The problem for the small insurance companies is that the companies
take the best of the risk. Insurance companies are very aboveboard with that.
Recently, the Health Association of America addressed this very issue and worked
out a proposal that would limit the amount the premiums could go up if there were
significant claims in a group. Itwould provide people with protection ifthey left one
group and went to another. But the problem is that insurance companies, as I said,
aren't the biggest provider of care, and you need to bring in others, the self-insured
companies, the Blue Cross-Blue Shield organizations, and then you have to have the
backup ofthe states that are willing to fund some uninsurable poolswhen the claims
get too great for any of the private organizations. The problem is getting these
self-insured companies and the states to agree to this fundingbecause it's money out
oftheir pockets.
DR. MAHONEY: Is it the case that people can lose health care benefits they currently
have and can't replace them if they leave that job or region because of having a
pre-existing condition? In a country where we have valued mobility and indepen-
dence of choice, we have created a system in which, for those who suffer these
handicaps ofillness, theycan neverleave that place. They'll neverbe insurable again.
DR. POKORSKI: There has been an attempt, endorsed by the National Association of
Insurance Commissioners, to create high-risk pools to provide insurance entitle-
ments for such people. We need adequate health care and adequate entitlement;
there should be a social consensus that we will support adequate health care in this
society and that we will dowhat's necessary to create a society like that.
60QUESTIONS FOR PANEL II
QUESTION: One way that the genetic test is different from all the other tests that we
do is that it tells us something not only about our patients but about their families.
Does the combination of the availability of that information and the data base
provide some risk in the way insurance companies will use that data?
DR. POKORSKI: We would treat it in the same manner that we treat current data. We
would not use data on one family member on another family member, for example.
Even within a company, you often hear concerns that tests will be done by health
insurers, claims would be submitted for genetic tests, and then, when that person
applies for health insurance, the same company would use the information that a test
was done; then theywould go back to the file to see what the test was. But companies
don't use claim information to determine whether or not somebody can be accepted
for a health insurance policy. We don't have that kind of internal use of information
at all. It'sjust not done.
DR. BILLINGS: In our survey, there were two examples of situations a little like that.
One was an employment decision, where a woman was denied employment in a
public institution because of a very strong family history of psychiatric illness. She
had not had psychiatric illness, but a strong family history; thus, the hereditary nature
does play a role in the employment. There were two reports of pregnancies in
families where a child with cystic fibrosis had been born, and the pregnancies had
undergone prenatal screening, which had detected fetuses that had the susceptible
genotype. The families chose not to terminate those pregnancies and to have those
children. There was disagreement between the insurer, an HMO in both cases, and
the family as to a limitation on the coverage for the pregnancy and the child who was
born.
DR. POKORSKI: That's the kind ofthing that the insurance industry likes to hear about.
Ifthat happened, we would like to hear details about it, if possible, so we could stop
that practice. There are HMOs which have nothing to do with insurance companies.
When you say "HMOs," people think of insurance companies, but it may not have
been an insurance company. This position may have been an independent decision
by the attending physician. Paul was nice enough to let me review a draft ofhis paper.
I have agreatproblemseeing howthis incident could have happened, because, in the
case cited, the HMO apparently told the people that, although they were already
covered, not only would the insurer not pay for the new child's care, they would not
pay for the pregnancy; they wouldn't pay for prenatal care, and they wouldn't pay for
the care of the child who already had cystic fibrosis. It seems absolutely mind-
boggling that this situation could have happened. I suspect that something major was
lost in the translation.
DR. BILLINGS: Those cases were reported to me by genetic counselors; I don't have
documentation; I was just informed. In another instance, in the Ehlers-Danlos
Society, where I recently spoke, people said that their child had a form ofEDS which
required a number of surgeries; at some point, the insurance company canceled
them.
COMMENT: We have assumed responsibility in our society to support a horrendous
military budget. We've assumed the responsibility to send people to the moon, to
Venus, and God knows where. Whywe can't scrap private insurance completely and
assume the responsibility of public health insurance for everybody? This change
would be far less than the cost to go to the moon, and we'd all be better off.
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COMMENT: The underlying principle of any insurance company is that it is an
institution that exists to make a profit out ofpeople's existing or future disability and
suffering. If we did have a system of guaranteed health care provided for every
person in ourcountry, these problems that insurance companies cause forus in terms
of genetic testing would be unnecessary and irrelevant. We should fight for a
nationalized health care system. Assuming for the moment that people with equal
risks pay the same amount, however, the assumption must be made that the
assessment ofrisk is accurate. That requires an understanding ofgenetics.
DR. POKORSKI: If we had national health insurance, we probably wouldn't need
private health insurance; I grant that. But that's the system we have right now. I'm
not so sure, if you had national health insurance, that it would be problem-free. If
you look at Canada's or Britain's system, where things are going broke, it's hard to
get access tothe system. With regard to risk assessment, we can't accuratelytellwhen
somebody is going to die. We try to put people into reasonable groups, based upon
statistics that, within a group, can be highly accurate. As long as we have a large
number ofpeople within that group, and we can use the risk selection tools available
to us, we can make fairly accurate risk assessments. There is a tremendous amountof
more genetic information than I will ever know. You people are obviously real
specialists, and I'm very much aware of that. That's why we lean on attending
physician reports so strongly.
DR. MAHONEY: The rights ofprivacy and autonomy are major concerns, and we may
have to fight very, very hard to maintain those as we move into this era of data
collection and identification. We mayhave togive up the benefits ofcollected data in
data banks; the two may not be compatible. We must get across the message that the
carrying of handicapping genetic information or abnormal genetic information or
defective genetic information, orwhatever terminology we would like, is common to
each one ofus and that, as these genes are identified in this next decade, all ofus are
going to have one or more ofthem. Ifwe could begin to view ourselves as imperfect
genetically, and tell everybody else that, starting with young children, maybe we will
have less concern about protecting our privacy and feeling that we will be discrimi-
nated against.
DR. SEASHORE: This concludes the symposium and the panel discussion. I want to
thank our speakers, our organizing committee, our funding and spiritual strength
from New England Regional Genetics Group, and from the Bureau ofMaternal and
Child Health, and, most of all, our responsive and excited audience. We've heard a
lot of interesting things today; we will go home with much fuel for discussion, for
policy making, and forbetter care ofourpatients.
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